Cargando…

Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941478/ https://www.ncbi.nlm.nih.gov/pubmed/35298618 http://dx.doi.org/10.1182/bloodadvances.2021005192

Ejemplares similares

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
Publicado: (2022)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.
Publicado: (2022)

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.
Publicado: (2022)

Bornhauser B, Cario G, Rinaldi A, et al. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv. 2020;4(17):4052-4064.
Publicado: (2022)

Nahui Olin : una mujer de los tiempos modernos.

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Off the hook: what Olin might mean.
por: Brown, K S
Publicado: (1997)

Deen D, Butter F, Daniels DE, et al. Identification of the transcription factor MAZ as a regulator of erythropoiesis. Blood Adv. 2021;5(15):3002-3015.
Publicado: (2022)

Singh A, Brandow AM, Panepinto JA. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 2021;5(7):1915-1921.
Publicado: (2022)

Duque-Afonso J, Ewald S, Ihorst G, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021;5(21):4327-4337.
Publicado: (2022)

Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
Publicado: (2022)

La guerra de Nahui Olin y otros amores /
por: Gutiérrez Trujillo, Gonzalo

Eshel A, Sharon I, Nagler A, et al. Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. Blood Adv. 2022;6(2):568-573.
Publicado: (2022)

Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919-3930.
Publicado: (2022)

Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022;6(11):3220-3229.
Publicado: (2022)

Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016.
Publicado: (2022)

Does hyperthyroidism worsen prognosis of thyroid carcinoma? A retrospective analysis on 2820 consecutive thyroidectomies
por: Medas, Fabio, et al.
Publicado: (2018)

Xu S, Wang S, Xing S, et al. KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 2021;5(17):3241-3253.
Publicado: (2022)

Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021;5(20):3913-3918.
Publicado: (2022)

Up-to-date on mortality in COPD - report from the OLIN COPD study
por: Lindberg, Anne, et al.
Publicado: (2012)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208.
Publicado: (2016)

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
Publicado: (2021)

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
por: Foekens, J A, et al.
Publicado: (1999)

Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT
por: Hirabayashi, Shigeki, et al.
Publicado: (2021)

1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019)

Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study
por: Ito, Ayumu, et al.
Publicado: (2021)

28.10 Effects of the COVID-19 Pandemic on the Mental Health of Children With Psychiatric Disorders
por: Abdallah, Maryam, et al.
Publicado: (2021)

Erratum for the Research Article: “Dynamic conservation for migratory species” by M. Reynolds, B. L. Sullivan, E. Hallstein, S. Matsumoto, S. Kelling, M. Merrifield, D. Fink, A. Johnston, W. M. Hochachka, N. E. Bruns, M. E. Reiter, S. Veloz, C. Hickey, N. Elliot, L. Martin, J. W. Fitzpatrick, P. Spraycar, G. H. Golet, C. McColl and S. A. Morrison
Publicado: (2018)

The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study
por: Sawalha, Sami, et al.
Publicado: (2019)

Make Your Cake and Eat It: Refueling of Immune Fitness in AML Post Allo-HCT Using Baking Soda
por: Tonks, Alex
Publicado: (2021)

Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study
por: Zecca, Marco, et al.
Publicado: (2019)

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering
por: Ye, Yishan, et al.
Publicado: (2022)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

2820. Clinical Outcomes in Patients Who Receive a One-Time Aminoglycoside Dose for ESBL Enterobacterales or Pseudomonas aeruginosa cystitis
por: Bouwman, Kelsey, et al.
Publicado: (2023)

Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS)
por: Versluys, Birgitta, et al.
Publicado: (2015)

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes
por: Steinhardt, M. J., et al.
Publicado: (2020)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

KEK-CERN Collaboration Meeting on the RF System of LEIR (KEK 28.10.-1.11.2002)
por: Rossi, C
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_142mrkb2f1jg6oe64emlear3np